DE69740162D1 - Verwendung eines Pleuromutilinderivats in der Veterinärmedizin - Google Patents

Verwendung eines Pleuromutilinderivats in der Veterinärmedizin

Info

Publication number
DE69740162D1
DE69740162D1 DE69740162T DE69740162T DE69740162D1 DE 69740162 D1 DE69740162 D1 DE 69740162D1 DE 69740162 T DE69740162 T DE 69740162T DE 69740162 T DE69740162 T DE 69740162T DE 69740162 D1 DE69740162 D1 DE 69740162D1
Authority
DE
Germany
Prior art keywords
veterinary medicine
pleuromutilin derivative
veterinary
pleuromutilin
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69740162T
Other languages
English (en)
Inventor
David George Sidney Burch
Paul Howard Ripley
Erich Zeisl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614014.0A external-priority patent/GB9614014D0/en
Priority claimed from GBGB9614015.7A external-priority patent/GB9614015D0/en
Priority claimed from GBGB9614012.4A external-priority patent/GB9614012D0/en
Priority claimed from GBGB9614016.5A external-priority patent/GB9614016D0/en
Priority claimed from GBGB9614013.2A external-priority patent/GB9614013D0/en
Priority claimed from GBGB9614019.9A external-priority patent/GB9614019D0/en
Priority claimed from GBGB9614018.1A external-priority patent/GB9614018D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of DE69740162D1 publication Critical patent/DE69740162D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Feed For Specific Animals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69740162T 1996-07-04 1997-07-03 Verwendung eines Pleuromutilinderivats in der Veterinärmedizin Expired - Lifetime DE69740162D1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9614014.0A GB9614014D0 (en) 1996-07-04 1996-07-04 Organic compounds
GBGB9614017.3A GB9614017D0 (en) 1996-07-04 1996-07-04 Organic compounds
GBGB9614015.7A GB9614015D0 (en) 1996-07-04 1996-07-04 Organic compounds
GBGB9614012.4A GB9614012D0 (en) 1996-07-04 1996-07-04 Organic compounds
GBGB9614016.5A GB9614016D0 (en) 1996-07-04 1996-07-04 Organic compounds
GBGB9614013.2A GB9614013D0 (en) 1996-07-04 1996-07-04 Organic compounds
GBGB9614019.9A GB9614019D0 (en) 1996-07-04 1996-07-04 Organic compounds
GBGB9614018.1A GB9614018D0 (en) 1996-07-04 1996-07-04 Organic compounds

Publications (1)

Publication Number Publication Date
DE69740162D1 true DE69740162D1 (de) 2011-05-12

Family

ID=27571326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69740162T Expired - Lifetime DE69740162D1 (de) 1996-07-04 1997-07-03 Verwendung eines Pleuromutilinderivats in der Veterinärmedizin

Country Status (25)

Country Link
US (1) US6130250A (de)
EP (4) EP0910363B1 (de)
JP (1) JP4165769B2 (de)
CN (1) CN1121216C (de)
AT (2) ATE509625T1 (de)
AU (1) AU718701B2 (de)
BG (1) BG64369B1 (de)
BR (1) BR9710208A (de)
CA (1) CA2256514C (de)
CZ (4) CZ298444B6 (de)
DE (1) DE69740162D1 (de)
DK (2) DK1813272T3 (de)
ES (2) ES2364414T3 (de)
GB (1) GB9614017D0 (de)
HU (1) HU230325B1 (de)
IL (1) IL127299A (de)
NO (1) NO326117B1 (de)
NZ (1) NZ333261A (de)
OA (1) OA10951A (de)
PL (1) PL189204B1 (de)
PT (2) PT910363E (de)
RU (1) RU2197237C2 (de)
SK (4) SK286445B6 (de)
UA (1) UA56173C2 (de)
WO (1) WO1998001127A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI260220B (en) * 1999-11-22 2006-08-21 Novartis Ag A pharmaceutical composition for the transdermal treatment of bacterial infections in animals
TWI228048B (en) * 1999-12-09 2005-02-21 Novartis Ag New formulation
GB0017031D0 (en) * 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
US6682762B2 (en) * 2001-10-09 2004-01-27 Heart-O-Dixie Animal Nutrition, Llc Poultry and livestock feed additive
CO5390081A1 (es) 2001-11-28 2004-04-30 Novartis Ag Compuestos organicos
EP1686115A1 (de) * 2005-01-26 2006-08-02 Novartis AG Organische Säureadditionssalze von Valnemulin
DE102006021493B4 (de) * 2006-05-09 2010-04-01 Bruker Daltonik Gmbh Massenspektrometrische Messung mikrobieller Resistenzen
EP2014645A1 (de) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin-derivate und ihre Verwendung als antimikrobielles Wirkungsmittel
CN101690717B (zh) * 2009-09-30 2013-03-06 北京大北农动物保健科技有限责任公司 一种兽用沃尼妙林及其盐的预混剂及制备方法
CN102415989A (zh) * 2011-09-30 2012-04-18 上海恒丰强动物药业有限公司 盐酸沃尼妙林溶液剂及其制备方法
CN103520099A (zh) * 2013-10-30 2014-01-22 王玉万 含有效成份为沃尼妙林的长效注射剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) * 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
US4247542A (en) * 1978-06-22 1981-01-27 Eli Lilly And Company A-40104 Antibiotics and process for production thereof
DE3405632A1 (de) * 1984-02-17 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue pleuromutilinderivate, verfahren zu ihrer herstellung und ihre verwendung
EP0153277B1 (de) * 1984-02-17 1987-08-26 Sandoz Ag Neue Pleuromutilinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
HU208115B (en) * 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
AT392272B (de) * 1989-10-03 1991-02-25 Biochemie Gmbh Verfahren zur herstellung eines pleuromutilinderivats und seiner saeureadditionssalze
AT400674B (de) * 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
CN1039585C (zh) * 1993-01-01 1998-08-26 生化企业 截短侧耳素衍生物与环糊精的配合物和含有它的药物制剂

Also Published As

Publication number Publication date
EP1810672A1 (de) 2007-07-25
AU718701B2 (en) 2000-04-20
SK2799A3 (en) 1999-09-10
IL127299A (en) 2005-05-17
EP1808171A1 (de) 2007-07-18
NO986198L (no) 1998-12-30
ATE503475T1 (de) 2011-04-15
DK0910363T3 (da) 2011-09-05
JP2000514072A (ja) 2000-10-24
PL330726A1 (en) 1999-05-24
UA56173C2 (uk) 2003-05-15
NO326117B1 (no) 2008-09-29
CZ298385B6 (cs) 2007-09-19
CZ298446B6 (cs) 2007-10-03
AU3692997A (en) 1998-02-02
ATE509625T1 (de) 2011-06-15
PT910363E (pt) 2011-05-31
EP1813272A1 (de) 2007-08-01
IL127299A0 (en) 1999-09-22
OA10951A (en) 2003-02-26
SK285711B6 (sk) 2007-06-07
HUP9903103A2 (hu) 2000-02-28
ES2360813T3 (es) 2011-06-09
CZ298445B6 (cs) 2007-10-03
EP0910363A1 (de) 1999-04-28
ES2364414T3 (es) 2011-09-01
EP0910363B1 (de) 2011-05-18
NZ333261A (en) 2000-09-29
CA2256514C (en) 2006-11-28
CN1223576A (zh) 1999-07-21
SK286445B6 (sk) 2008-10-07
BG64369B1 (bg) 2004-12-30
PT1813272E (pt) 2011-04-29
EP1813272B1 (de) 2011-03-30
CN1121216C (zh) 2003-09-17
CA2256514A1 (en) 1998-01-15
BR9710208A (pt) 1999-08-10
HUP9903103A3 (en) 2000-04-28
GB9614017D0 (en) 1996-09-04
CZ298444B6 (cs) 2007-10-03
JP4165769B2 (ja) 2008-10-15
WO1998001127A1 (en) 1998-01-15
PL189204B1 (pl) 2005-07-29
SK285857B6 (sk) 2007-09-06
DK1813272T3 (da) 2011-07-18
US6130250A (en) 2000-10-10
HU230325B1 (hu) 2016-02-29
SK286431B6 (sk) 2008-10-07
BG103002A (en) 1999-09-30
CZ438198A3 (cs) 1999-03-17
RU2197237C2 (ru) 2003-01-27
NO986198D0 (no) 1998-12-30

Similar Documents

Publication Publication Date Title
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
ATE120644T1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
DE69740162D1 (de) Verwendung eines Pleuromutilinderivats in der Veterinärmedizin
DE69327399D1 (de) Verwendung von stoffen für die herstellung eines medikaments für geflügel
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
RU94044454A (ru) Ингибитор аутоимунных заболеваний
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
RU94044321A (ru) Средство повышения либидо у женщин постклимактерического периода
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
EP0361791A3 (de) Azacyclische Verbindungen, verwendbar als Arzneimittel
ATE339202T1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
ATE232387T1 (de) Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
SE9101840D0 (sv) New medicinal use
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
NO902157D0 (no) Butensyrederivater for terapeutisk anvendelse.
DE69007065T2 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung